U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H26N2OS2
Molecular Weight 422.606
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IZONSTERIDE

SMILES

[H][C@@]12CCC3=CC(SC4=NC5=C(CC)C=CC=C5S4)=CC=C3[C@@]1(C)CCC(=O)N2C

InChI

InChIKey=VMGWGDPZHXPFTC-HYBUGGRVSA-N
InChI=1S/C24H26N2OS2/c1-4-15-6-5-7-19-22(15)25-23(29-19)28-17-9-10-18-16(14-17)8-11-20-24(18,2)13-12-21(27)26(20)3/h5-7,9-10,14,20H,4,8,11-13H2,1-3H3/t20-,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H26N2OS2
Molecular Weight 422.606
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

IZONSTERIDE, a benzoquinolinone, is a selective inhibitor of the 5-alpha reductase, with antagonistic effect on both the type I (liver, skin, hair follicles) and type II (prostate) isoforms of the enzyme. It is a competitive inhibitor of type I 5-alpha reductase and a non-competitive inhibitor of type II 5-alpha reductase. It was under development for the treatment of prostatic cancer.

Originator

Approval Year

PubMed

Sample Use Guides

In Vitro Use Guide
IZONSTERIDE inhibits 5-alpha reductase activity in human scalp skin (Ki=28.7+/-1.87 nM) and prostatic homogenates (Ki=10.6+/-4.5 nM).
Substance Class Chemical
Record UNII
A5E8C36F34
Record Status Validated (UNII)
Record Version